ZA201203551B - Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites - Google Patents

Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Info

Publication number
ZA201203551B
ZA201203551B ZA2012/03551A ZA201203551A ZA201203551B ZA 201203551 B ZA201203551 B ZA 201203551B ZA 2012/03551 A ZA2012/03551 A ZA 2012/03551A ZA 201203551 A ZA201203551 A ZA 201203551A ZA 201203551 B ZA201203551 B ZA 201203551B
Authority
ZA
South Africa
Prior art keywords
mva
insertion sites
virus containing
recombinant modified
vaccinia
Prior art date
Application number
ZA2012/03551A
Other languages
English (en)
Inventor
Bernard Moss
Patricia L Earl
Linda S Wyatt
Original Assignee
The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer filed Critical The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer
Publication of ZA201203551B publication Critical patent/ZA201203551B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2012/03551A 2009-10-16 2012-05-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites ZA201203551B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25232609P 2009-10-16 2009-10-16
PCT/US2010/052929 WO2011047324A1 (en) 2009-10-16 2010-10-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Publications (1)

Publication Number Publication Date
ZA201203551B true ZA201203551B (en) 2013-01-30

Family

ID=43297031

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/03551A ZA201203551B (en) 2009-10-16 2012-05-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Country Status (8)

Country Link
US (2) US9133480B2 (enExample)
EP (1) EP2488649B1 (enExample)
JP (1) JP5789263B2 (enExample)
AU (1) AU2010306559B2 (enExample)
CA (1) CA2777744C (enExample)
DK (1) DK2488649T3 (enExample)
WO (1) WO2011047324A1 (enExample)
ZA (1) ZA201203551B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142479A2 (en) * 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2015320409B2 (en) 2014-09-26 2019-03-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Virus-based expression vectors and uses thereof
US11701418B2 (en) 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
US20190038659A1 (en) 2015-09-29 2019-02-07 The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing amyotrophic lateral sclerosis
CA3011014A1 (en) 2016-01-08 2017-07-13 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
WO2017210181A1 (en) * 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2019152746A2 (en) 2018-01-30 2019-08-08 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
WO2019217922A1 (en) 2018-05-11 2019-11-14 City Of Hope Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
CA3156346A1 (en) * 2019-10-02 2021-04-08 Bionoxx Inc. Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
IL295482A (en) 2020-02-14 2022-10-01 Geovax Inc Vaccines and their uses to induce an immune response to sars-cov2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
CA3206004A1 (en) 2021-02-02 2022-08-11 Mary Jo Hauser Viral constructs for use in enhancing t-cell priming during vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
EP1610816B1 (en) 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus expressing modified hiv envelope, gag, and pol genes
WO2008142479A2 (en) * 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
EP2199400A1 (en) * 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites

Also Published As

Publication number Publication date
CA2777744C (en) 2019-09-24
CA2777744A1 (en) 2011-04-21
AU2010306559B2 (en) 2015-07-16
US20120263750A1 (en) 2012-10-18
EP2488649A1 (en) 2012-08-22
US20160040135A1 (en) 2016-02-11
DK2488649T3 (da) 2019-06-17
AU2010306559A1 (en) 2012-06-07
JP2013507935A (ja) 2013-03-07
WO2011047324A1 (en) 2011-04-21
US9879231B2 (en) 2018-01-30
US9133480B2 (en) 2015-09-15
JP5789263B2 (ja) 2015-10-07
EP2488649B1 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
DK2488649T3 (da) Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
EP2350525A4 (en) PHOSPHORUS AUTHENTICATION SYSTEM
EP2283418A4 (en) AUTHENTICATION WITH MULTIPLE FACTORS, MULTICANAUX
DK2459715T3 (da) Fremgangsmåde til at oprense rekombinant adamts13 og andre proteiner og sammensætninger deraf
ZA200804356B (en) Stabilizing formulations for recombinant viruses
ZA201201627B (en) Compounds as tyrosine kinase modulators
AU317297S (en) Mask prongs
PL2230943T3 (pl) Pediatryczna mieszanina włókien
GB0823327D0 (en) Authentication
EP2128667A4 (en) GRID POLARIZER
PT2882236T (pt) Controlo de potência de ligação ascendente para terminais limitados em potência
IL215599A0 (en) Papillomavirus e2 polypeptide used for vaccination
EP2359182A4 (en) COLOR COMBINATOR WITH POLARIZATION CONVERSION
EP2319133A4 (en) TERMINATOR
EP2299471A4 (en) Quadrupole mass analyzer
IL200073A (en) Immediate protection against pox viral infections using mva
ZA201103645B (en) Single-time vaccines
GB0721295D0 (en) Improved uplink
GB0823560D0 (en) Virus
GB0812088D0 (en) Insulating batt with multidirectional tearability
GB0809867D0 (en) Improved methods for high field asymmetric waveform spectrometry (HIFAWS)
GB0908473D0 (en) Improved methods for high field asymmetric waveform spectrometry(HiFAWS)
GB0816411D0 (en) Improved methods for high field asymmetric waveform spectrometry (HiFAWS)
PH32008001041S1 (en) Blender
GB0818744D0 (en) Usb pvr bb